Completed enrollment in Phase 2 BESTOW trial assessing tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Presented updat ...
IRVINE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon”) (Nasdaq: ELDN) today announced a summary of 2024 accomplishments and provided guidance for anticipated 2025 ...
Increased delay to lung transplantation for women candidates: gender-based disparity matters in the lung transplant ...
[87] Two patients with necrobiosis lipoidica were treated for 8 weeks with 0.1% tacrolimus ointment twice daily; one showed a considerable reduction of the inflammation and regression of the ...
Express US takes a look at the products which have been recalled by the Food and Drug Administration since the start of January.
Cyclosporine (CsA) and tacrolimus (TAC) are the primary immunosuppressants used in the treatment of SRNS. Currently, there is a lack of comprehensive safety evaluations of CsA and TAC in pediatric NS ...
Biocon said that it's wholly owned subsidiary, Biocon Pharma, has received approval for Tacrolimus capsule in 0.5mg, 1mg and 5mg strengths, from the National Medical Products Administration (NMPA), ...
Bangalore: Biocon has announced that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received approval for Tacrolimus capsule in 0.5mg, 1mg and 5mg strengths, from the National ...
Tacrolimus, an immunosuppressant, is used to reduce organ rejection in transplant patients by suppressing the immune system. This approval broadens Biocon’s portfolio of complicated medicinal ...
Biotechnology firm BioconLtd on Thursday (January 2) announced that its wholly owned subsidiary, Biocon Pharma Ltd, has received approval from the National Medical Products Administration (NMPA) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback